Published on
Last updated on
Beijing MPA Clarifies Electronic Customs Clearance Pilot for Imported Drugs

On October 23, 2026, the Beijing Municipal Medical Products Administration (Beijing MPA) published an implementation notice providing further guidance on the electronic customs clearance pilot for imported drugs, including medicinal materials, at Beijing ports. The pilot was launched on September 21, 2026, following the National Medical Products Administration (NMPA) and General Administration of Customs (GACC) Announcement No.91 of 2026.
The pilot enables the electronic issuance of import customs clearance documents without changing existing drug requirements. No specific end date has been announced, and implementation remains subject to subsequent regulatory adjustments.
Previously, although import filing applications and approvals were processed online, companies still needed to collect paper customs clearance documents from the relevant administrative office. Under the pilot, reporting entities can now download and print the electronic documents directly through China’s International Trade Single Window platform following approval:
- Import Drug Customs Clearance Form
- Import Drug Port Inspection Notice
Both documents have the same legal effect as their paper equivalents, which remain valid throughout the pilot period. The electronic customs clearance form includes an official electronic seal and a QR code that enables verification of key document information and its validity.
Key Requirements for Participating Companies
The pilot does not change the underlying requirements for import filings. Reporting entities must continue to meet existing obligations for certificate verification, supporting documentation and recordkeeping.
Under China's Measures for the Administration of Drug Imports, the authenticity of relevant drug registration certificates and import permits must continue to be verified. To facilitate this process, reporting entities may upload electronic copies of the relevant certificates through the "Attachment Information" section of the International Trade Single Window platform.
Reporting entities must also ensure that:
- All submitted materials are authentic, complete and legible
- Supporting certificates are available for authenticity verification when required
- Electronic customs clearance documents are properly used and retained in accordance with applicable requirements
Final Thoughts
For foreign pharmaceutical companies importing products through Beijing ports, the pilot offers an opportunity to streamline administrative procedures by reducing reliance on physical document collection. Companies should coordinate with their Chinese importers and reporting entities to ensure they are familiar with the updated electronic document issuance and retrieval procedures.
Companies should ensure their Chinese partners:
- Have access to the relevant registration certificates and import permits and can provide them for authenticity verification when required
- Know how to use the International Trade Single Window to upload supporting certificates and submit accurate, complete and legible documentation
- Can download and retain electronic customs clearance documents, understand the updated platform procedures and know where to seek assistance if issues arise
Companies should also ensure supporting documents are up to date and consistent with the products being imported. Cisema can help review import documentation and coordinate with Chinese partners to ensure filings meet applicable requirements.
For support with pharmaceutical import documentation, customs clearance requirements and regulatory compliance in China, contact Cisema today.
Further Information
- Read about China's Drug Registration Electronic Submission Trial Program
- Get Cisema’s whitepaper on NMPA registration of drugs for human use in China.
References
- Beijing Municipal Medical Products Administration, Notice on Implementing the Pilot Program for Electronic Customs Clearance of Imported Drugs
- National Medical Products Administration and General Administration of Customs, Announcement on Matters Related to the Pilot Program for Electronic Customs Clearance of Imported Drugs at Beijing Ports (2026 No. 91) (国家药监局 海关总署关于在北京口岸开展进口药品通关电子化试点工作有关事项的公告(2026年第91号))
Connect with Cisema
With more than 20 years of experience and a team of over 100 specialists, Cisema helps global companies achieve compliance across Asia Pacific with confidence and accelerate market entry.
Stay Informed with Monthly News and Analysis
Stay informed with the latest regulatory changes, expert insights, and market opportunities across APAC, delivered straight to your inbox.


